Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#BreastCancerTreatment

Home » #BreastCancerTreatment
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope

Posted by By Mourabit Halima 2024.01.21
Editor's Note: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought…
Read More
Professor Ying Fan: Evolution of HR+/HER2- Early Breast Cancer Adjuvant Treatment Strategies and Risk Stratification—Based on the Chinese Perspective

Professor Ying Fan: Evolution of HR+/HER2- Early Breast Cancer Adjuvant Treatment Strategies and Risk Stratification—Based on the Chinese Perspective

Posted by By Peng Longmei 2024.01.21
Editor's Note Breast cancer is the most common malignancy in women, with an increasing incidence in recent years. HR+/HER2- breast cancer accounts for approximately 70% of all breast cancer cases,…
Read More
ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients

ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients

Posted by By Mourabit Halima 2024.01.19
Editor's Note: The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy…
Read More
Recent Posts
  • ESMO China Voice | Professor Jiesong Wang: The iPET-NCCN-IPI Model May Optimize Risk Stratification in Diffuse Large B-Cell Lymphoma
  • ESMO China Voice | Dr. Sicong Zhang: Refractory DLBCL Patients Share Similar Immune Signatures
  • ESMO China Voice | Dr. Cong Sun: Grade 3B Follicular Lymphoma Is an Independent Risk Factor Affecting Both PFS and OS
  • ESMO China Voice | Prof. Liang Wang: CD19/CD22 Bispecific CAR-T Therapy Demonstrates Remarkable Efficacy and Safety in R/R LBCL
  • 13th FACO Annual Academic Conference Grandly Held in Shanghai! Leading Experts from China, Japan, and South Korea Gather to Foster Clinical Oncology
Recent Comments
    Archives
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top